JOHNSON & JOHNSON — Director's Dealing 2022

Nov 23, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2022-11-22

Reporting Person: Taubert Jennifer L (EVP, WW Chair, Pharmaceuticals)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-22	Common Stock	M	76923.0000	$72.5400	Acquired	203379.0010	Direct
2022-11-22	Common Stock	S	76923.0000	$176.7794	Disposed	126456.0010	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-22	Employee Stock Options (Right to Buy)	$72.5400	M	76923.0000	Disposed	2023-01-13	Common Stock (76923.0000)	Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $176.525 to $177.190. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.